Tag: sale

DALLAS, July 15, 2025 (GLOBE NEWSWIRE) -- Veritex Holdings, Inc. (Nasdaq: VBTX), the parent holding company for Veritex Community Bank, today announced a date change for release of its second quarter 2025 earnings results. Veritex will now release its second quarter 2025 earnings results before the opening of the market on Friday, July 18, 2025. The earnings release will be available on Veritex’s website, https://ir.veritexbank.com/.

PLEASE CLICK HERE TO SUBMIT YOUR CONTACT INFORMATION

Hong Kong, July 15, 2025 (GLOBE NEWSWIRE) -- K-Tech Solutions Company Limited (“KMRK” or the “Company”) is an established toy products design house specialized in the development of infant and pre-school educational toys and learning kits. The Company is headquartered in Hong Kong to provide full-fledged product development solutions to toy brands throughout the entire development stage of toy products from design, prototype testing, production management, quality control to after-sales services. K-Tech Solutions Company Limited today announced the pricing of its firm commitment initial public offering of an aggregate 1,600,000 Class A Shares (the “Offering”) priced at US$4.00 per share (the “Offering Price”). In addition, the Company has granted the underwriter a 30-day option ("Overallotment") to purchase up to an additional 240,000 Class A Shares at the initial public offering price, less underwriting discounts and commissions.

BETHESDA, Md., July 15, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase common stock in an underwritten public offering. Gain expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and/or the warrants offered in the offering. All of the securities are being offered by the Company.

PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of a best-efforts public offering of 12,000,000 units. Each unit consists of one common share (or pre-funded warrant (“Pre-Funded Warrant”) in lieu thereof) and one warrant (the “Warrants”). Each unit is being sold to the public at a price of $1.25 per unit (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of $15 million, before deducting placement agent fees and offering expenses. Each Warrant is immediately exercisable, and entitles the holder to purchase one common share at an exercise price of $1.50 per share and will expire five years from the date of issuance. The common shares (or Pre-Funded Warrants) and Warrants can only be purchased together in the offering but will be issued separately.